NCT02651948CompletedPhase 4
Transperineal, MRI-guided, Prostate Biopsy
Transperineal, MRI-guided, Prostate Biopsy: First Step to Focal Treatment of Prostate Cancer
Source: ClinicalTrials.gov · Last updated 19 Dec 2025
Brief summary (registry, in English)
Primary purpose: Complications and rehospitalizations after transperineal prostate biopsy MRI-guided are reduced than transrectal prostate biopsies. Secondary purposes: * Patients tolerance after transperineal prostate biopsy MRI-guided is better than after transrectal prostate biopsies. * Core of transperineal prostate biopsies are better than core of transrectal prostate biopsies * Study of correlation between radiologic images and anatomopathologic result * Description of needle track during the procedure * Description of real time template saturation prostate biopsy * Comparison of transperineal prostate biopsy relevance according to EBM * Comparison of 1.5T MRI and 3T MRI for prostate cancer detection
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (actual)
- First submitted
- 23 Dec 2015
- Start date
- 1 May 2015
- Primary completion date
- 1 Aug 2023
- Lead sponsor
- University Hospital, Strasbourg, France
- Diseases
- Prostate cancer
- NCT number
- NCT02651948
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 90
- From 1 May 2015 to the primary completion date, 1 Aug 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Gleason \> 6 prostate cancer
- Metastatic prostate cancer
Other
- Contraindication to MRI
- Contraindication to general anesthesia
- Non-reversible hemostasis trouble
- Inability to give consent
Who the study is looking for
- Men
- 40 to 80 years' old
- Affiliation to French social health system
- Signed consent
- Prostate cancer suspicion based on prostate specific antigen (PSA) or digital rectal exam WITH abnormal MRI (Prostate Imaging Reporting and Data System score 3) AND negative transrectal prostate biopsies
- Patient treated by active surveillance for a low risk prostate cancer (T1c or T2a, Gleason = 6, PSA \< 10)
Age in the registry: 40 years to 80 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Service d'urologie Coordinator of this site? Confirm its status | Strasbourg | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.